Eli Lilly Expands Innovation Through Biopharma Collaborations
Eli Lilly has entered into licensing and research agreements with Hanmi Pharm (South Korea) and Haisco Pharmaceutical Group (China), gaining access to new drug candidates. The deals include an upfront payment of $75 million for sonefpeglutide, a biologic candidate in Phase 2 trials for short bowel syndrome.
Tickers: $LLY